Advanced Accelerator Applications S.A. (NASDAQ: AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate CancerFebruary 12, 2018 7:00 AM